Welcome to our dedicated page for Monte Rosa Therapeutics news (Ticker: GLUE), a resource for investors and traders seeking the latest updates and insights on Monte Rosa Therapeutics stock.
Monte Rosa Therapeutics develops molecular glue degrader medicines for serious diseases using its QuEEN discovery engine, which combines AI-guided chemistry, chemical libraries, structural biology and proteomics. The company’s news centers on clinical and preclinical updates for programs including MRT-8102, a NEK7-directed degrader for inflammatory disease biology; MRT-2359, a GSPT1-directed degrader studied in metastatic castration-resistant prostate cancer; and MRT-6160, a VAV1-directed degrader for immune-mediated diseases.
Recurring developments also include oncology discovery work such as cyclin E1-directed and CDK2-directed degrader programs, clinical supply and pharmaceutical collaboration activity, quarterly financial results, equity awards, capital resources and public-company governance updates.
Monte Rosa Therapeutics (Nasdaq: GLUE) reported Q1 2026 results and program updates on May 7, 2026. Key clinical highlights include MRT-8102 interim data showing CRP -85% and 94% of subjects below 2 mg/L, MRT-2359 tumor activity in mCRPC, and preclinical CCNE1 program with IND planned in H2 2026. Financially, cash and marketable securities were $671.2M, expected to support operations into 2029.
Monte Rosa Therapeutics (Nasdaq: GLUE) granted inducement equity awards to four newly hired non-executive employees under its 2026 Inducement Plan on May 1, 2026. The awards include non-qualified stock options for 38,925 shares at an $18.80 exercise price and 8,550 restricted stock units, with standard time-based vesting.
Monte Rosa Therapeutics (Nasdaq: GLUE) will present preclinical data on its CCNE1-directed molecular glue degrader, MRT-55811, at AACR on April 21, 2026. Data show potent, selective CCNE1 degradation, tumor regressions in CCNE1-amplified ovarian, breast, and gastric models, and superior selectivity versus CDK2 inhibitors.
The company expects to submit an IND for the program later in 2026.
Monte Rosa Therapeutics (Nasdaq: GLUE) reported Q4 and full‑year 2025 results and program updates on March 17, 2026. Key clinical highlights include MRT-8102 showing an 85% CRP reduction after four weeks and 94% of participants reaching CRP <2 mg/L. The company closed a $345M follow‑on financing and reports cash and marketable securities of $382.1M as of Dec 31, 2025, supporting operations into 2029.
Other items: favorable safety/tolerability data for MRT-8102; MRT-2359 showed 100% PSA responses in a 5/5 AR‑mutant mCRPC subset; planned Phase 2 starts in 2026–2027; Novartis and Roche collaborations provide milestone upside.
Monte Rosa Therapeutics (Nasdaq: GLUE) announced a supply agreement with Johnson & Johnson to support a planned Phase 2 study of MRT-2359 plus apalutamide for metastatic castration-resistant prostate cancer (mCRPC) with androgen receptor (AR) mutations.
The signal-confirming Phase 2 is expected to start in Q3 2026, will enroll up to 25 patients, and will assess PSA response, RECIST response, duration of response, PFS, rPFS, and safety. Prior positive Phase 1/2 combination data were presented on Feb 26, 2026.
Monte Rosa Therapeutics (Nasdaq: GLUE) reported updated Phase 1/2 data for MRT-2359 plus enzalutamide in heavily pretreated mCRPC patients, presented at ASCO GU on Feb 26, 2026. Key findings: 100% PSA response (5/5) and 100% RECIST disease control in AR-mutant patients; overall RECIST DCR 67% (10/15); 10 of 15 showed tumor size reductions. Safety was manageable with mainly Grade 1–2 AEs and no discontinuations for AEs. Company plans a signal-confirming Phase 2 in AR-mutant mCRPC starting Q3 2026 to assess PSA, RECIST, rPFS and safety.
Monte Rosa Therapeutics (Nasdaq: GLUE) announced management will present at three investor conferences in March 2026: TD Cowen (Mar 2), Barclays (Mar 10) and Jefferies Biotech on the Beach (Mar 11).
Presenters include CEO Markus Warmuth and CMO Filip Janku. Webcasts will be available via the company’s Events & Presentations page and archived for 30 days.
Monte Rosa Therapeutics (Nasdaq: GLUE) priced an underwritten public offering of 11,125,000 common shares at $24.00 per share and pre-funded warrants to purchase 1,375,000 shares at $23.9999 each. Gross proceeds are expected to be approximately $300 million, before underwriting discounts, commissions and expenses. The company granted underwriters a 30-day option to buy up to an additional 1,875,000 shares. All offered securities are being sold by Monte Rosa and the offering is expected to close on or about January 12, 2026, subject to customary closing conditions.
Jefferies, TD Cowen and Piper Sandler are joint book-running managers; Wedbush PacGrow and LifeSci Capital are passive bookrunners. The offering is made under an effective shelf registration statement declared effective March 31, 2025.
Monte Rosa Therapeutics (Nasdaq: GLUE) announced a proposed underwritten public offering of $200.0 million of common stock and, for certain investors, pre-funded warrants to purchase common stock, with underwriters granted a 30-day option to buy up to an additional $30.0 million. The offering is subject to market and other conditions and may not be completed as proposed. The securities will be offered under an effective shelf registration declared effective by the SEC on March 31, 2025. Jefferies, TD Cowen and Piper Sandler are joint book-running managers; Wedbush PacGrow and LifeSci Capital are passive bookrunners. A preliminary prospectus supplement will be filed with the SEC.
Monte Rosa Therapeutics (NASDAQ: GLUE) announced positive interim Phase 1 data for MRT-8102, a NEK7-directed oral molecular glue degrader targeting NLRP3/IL-1/IL-6 inflammation pathways. In Part 3 (24 subjects dosed for 4 weeks as of Dec 23, 2025) median hsCRP fell 85% and 94% of subjects reached hsCRP <2 mg/L from a median baseline of 6.3 mg/L. NEK7 degradation in peripheral T cells was ~80–90% across doses (5–400 mg). Median plasma IL-6 dropped 55%; two subjects had a 75% CSF IL-6 decrease. Safety was described as favorable with mainly mild–moderate AEs and no evidence of increased infection risk. Readout of the expanded study is anticipated in H2 2026, and a Phase 2 ASCVD study is planned for 2026.